Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells
- PMID: 12796698
- DOI: 10.1097/01.ju.0000070685.34760.5f
Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells
Abstract
Purpose: Metastasis to bone is an important cause of morbidity in advanced prostate cancer. Despite the typically sclerotic nature of prostatic bone metastases osteolysis has a significant role in the pathogenesis of this disease. The nitrogen containing bisphosphonates (N-BPs), such as pamidronate and zoledronic acid, have greatly enhanced potency for inhibiting bone resorption and inducing apoptosis in osteoclasts. We investigated the effects of N-BPs on prostate cancer cells.
Materials and methods: Cell viability was determined with an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymeyhoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) dye reduction assay. Cell cycle analysis, DNA fragmentation and caspase 3 activity were assessed using flow cytometry. Ras, Bcl-2 and Bax were quantified by Western blotting.
Results: Pamidronate and zoledronic acid decreased cell viability in the 3 human cell lines DU145, PC3 and LNCaP. These effects were associated with changes in cell cycle distribution, induction of DNA fragmentation and a decrease in the Bcl-2-to-Bax ratio, which are features of apoptotic cell death. Pre-incubation with caspase inhibitors attenuated the effects of zoledronic acid and caspase 3 activity was demonstrated in treated DU145 cells. Zoledronic acid induced loss of cell viability in DU145 cells was prevented by co-treatment with farnesol, suggesting that N-BPs cause inhibition of the mevalonate pathway and Ras prenylation. A decrease in active, membrane bound Ras in zoledronic acid treated DU145 cells was shown by Western blot analysis.
Conclusions: N-BPs induce apoptosis in prostate cancer via a caspase dependent mechanism. They have effects on protein prenylation via inhibition of the mevalonate pathway and impair membrane localization of Ras in prostate cancer cells.
Similar articles
-
Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation.BJU Int. 2004 Jul;94(1):164-70. doi: 10.1111/j.1464-4096.2004.04831.x. BJU Int. 2004. PMID: 15217454
-
Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells.Eur J Pharmacol. 2010 Sep 1;641(1):35-40. doi: 10.1016/j.ejphar.2010.05.010. Epub 2010 May 25. Eur J Pharmacol. 2010. PMID: 20519142
-
A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.Anticancer Res. 1999 Jan-Feb;19(1A):51-60. Anticancer Res. 1999. PMID: 10226524
-
Bisphosphonates: preclinical review.Oncologist. 2004;9 Suppl 4:3-13. doi: 10.1634/theoncologist.9-90004-3. Oncologist. 2004. PMID: 15459425 Review.
-
Antitumor effects of bisphosphonates.Cancer. 2003 Feb 1;97(3 Suppl):840-7. doi: 10.1002/cncr.11128. Cancer. 2003. PMID: 12548584 Review.
Cited by
-
Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.BMC Cancer. 2006 Mar 15;6:60. doi: 10.1186/1471-2407-6-60. BMC Cancer. 2006. PMID: 16539721 Free PMC article.
-
Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.J Endocrinol Invest. 2010 Apr;33(4):244-9. doi: 10.1007/BF03345787. Epub 2009 Nov 12. J Endocrinol Invest. 2010. PMID: 19915386
-
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma.Lung Cancer (Auckl). 2017 Jun 12;8:39-44. doi: 10.2147/LCTT.S135802. eCollection 2017. Lung Cancer (Auckl). 2017. PMID: 28652837 Free PMC article.
-
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma.Cancer Res. 2007 Dec 1;67(23):11438-46. doi: 10.1158/0008-5472.CAN-07-1882. Cancer Res. 2007. PMID: 18056472 Free PMC article.
-
Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.Trials. 2018 Aug 29;19(1):467. doi: 10.1186/s13063-018-2851-9. Trials. 2018. PMID: 30157910 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials